ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice

Background: Filgotinib (FIL) is a selective JAK1 inhibitor with an affinity 30-fold higher than JAK2, approved to treat moderate to severe active rheumatoid arthritis (RA), in adults with inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Methods: We co...

Descripción completa

Detalles Bibliográficos
Autores principales: Benucci, Maurizio, Bardelli, Marco, Cazzato, Massimiliano, Laurino, Elenia, Bartoli, Francesca, Damiani, Arianna, Li Gobbi, Francesca, Panaccione, Anna, Di Cato, Luca, Niccoli, Laura, Frediani, Bruno, Mosca, Marta, Guiducci, Serena, Cantini, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532886/
https://www.ncbi.nlm.nih.gov/pubmed/37763071
http://dx.doi.org/10.3390/jpm13091303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532886/
https://www.ncbi.nlm.nih.gov/pubmed/37763071
http://dx.doi.org/10.3390/jpm13091303

Ejemplares similares